Table of Contents Author Guidelines Submit a Manuscript
Volume 2011, Article ID 165837, 7 pages
Review Article

Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents

Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

Received 26 June 2010; Revised 18 April 2011; Accepted 20 April 2011

Academic Editor: Alberto Pappo

Copyright © 2011 Keri S. Stewart and Eugenie S. Kleinerman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ewing's sarcoma accounts for a disproportionately high portion of the overall pediatric mortality rate compared to its rare incidence in the pediatric population. Little progress has been made since the introduction of traditional chemotherapies, and understanding the biology of the tumor is critical for developing new therapies. Ewing's sarcomas rely on a functional vascular supply, which is formed by a combination of angiogenesis and vasculogenesis. Recent insights into the molecular regulation of bone marrow (BM) cell participation in vascular development have identified VEGF, SDF-1α, and DLL4 as critical players in the vasculogenesis process. Clinical trials using vascular targeting agents, specifically targeting VEGF or DLL4, are underway.